Document is current
Any future updates will be listed below
-
Authors
Chhatwal, Jasmeer P. https://orcid.org/0000-0002-7792-1698
Schultz, Aaron P.
Dang, Yifan
Ostaszewski, Beth
Liu, Lei https://orcid.org/0000-0002-4604-4629
Yang, Hyun-Sik https://orcid.org/0000-0002-8318-0443
Johnson, Keith A.
Sperling, Reisa A.
Selkoe, Dennis J.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (P01AG036694, R01AG006173, R01AG062667)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Doris Duke Charitable Foundation (Clinical Scientist Development Award)
- License Information
-
More Information
Article History
Received: 11 June 2020
Accepted: 12 October 2020
First Online: 27 November 2020
Competing interests
: The authors declare no competing interests with regards to the content or interpretation of the data in the present study. Dr. Chhatwal has served on a medical advisory board for Otsuka Pharmaceuticals. Dr. Schultz has served on medical advisory boards for Janssen Pharmaceuticals and Biogen. Drs Sperling and Johnson are involved in public–private partnership clinical trials sponsored by the NIH and Eli Lilly and Co., who owns the distribution rights to Flortaucipir (AV-1451), but they do not have any personal financial relationship with Eli Lilly. Dr. Selkoe is a director and consultant for Prothena Biosciences.
